Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy resistance

JAK inhibition shows two faces in prostate cancer

Nature Cancer volume 3, pages 1021–1023 (2022)Cite this article

Subjects

Therapeutic resistance in prostate cancer can be driven by lineage plasticity, but the mechanisms behind this are unclear, and therapies to prevent or reverse the process are nonexistent. A new study reveals the JAK/STAT signaling axis as a driver of lineage plasticity with tremendous therapeutic potential.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: JAK/STAT signaling and lineage plasticity.

References

  1. Bluemn, E. G. et al. Cancer Cell 32, 474–489 e6 (2017).

    Article  CAS  Google Scholar 

  2. Beltran, H. et al. Nat. Med. 22, 298–305 (2016).

    Article  CAS  Google Scholar 

  3. Beltran, H. et al. J. Clin. Invest. 130, 1653–1668 (2020).

    Article  Google Scholar 

  4. Berger, A. et al. 129, 3924-3940 (2019).

  5. Augello, M. A. et al. Cancer Cell 35, 603–617 e8 (2019).

    Article  CAS  Google Scholar 

  6. Zhang, Z. et al. Cancer Cell 37, 584–598 e11 (2020).

    Article  CAS  Google Scholar 

  7. Ku, S. Y. et al. Science 355, 78–83 (2017).

    Article  CAS  Google Scholar 

  8. Brady, N. J. et al. Nat. Commun. 12, 3372 (2021).

    Article  CAS  Google Scholar 

  9. Lee, J. K. et al. Cancer Cell 29, 536–547 (2016).

    Article  CAS  Google Scholar 

  10. Dardenne, E. et al. Cancer Cell 30, 563–577 (2016).

    Article  CAS  Google Scholar 

  11. Bishop, J. L. et al. Cancer Discov. 7, 54–71 (2017).

    Article  CAS  Google Scholar 

  12. Mu, P. et al. Science 355, 84–88 (2017).

    Article  CAS  Google Scholar 

  13. Deng, S. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00431-9 (2022).

    Article  PubMed  Google Scholar 

  14. Tang, F. et al. Science 376, eabe1505 (2022).

    Article  CAS  Google Scholar 

  15. Irey, E. A. et al. Proc. Natl Acad. Sci. USA 116, 12442–12451 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

    Nicholas J. Brady

  2. Department of Urology, Weill Cornell Medicine, New York, NY, USA

    Christopher E. Barbieri

  3. Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA

    Christopher E. Barbieri

  4. Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA

    Christopher E. Barbieri

Authors
  1. Nicholas J. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher E. Barbieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher E. Barbieri.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brady, N.J., Barbieri, C.E. JAK inhibition shows two faces in prostate cancer. Nat Cancer 3, 1021–1023 (2022). https://doi.org/10.1038/s43018-022-00437-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00437-3

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer